# Quantum Bio Recovery Engine — Lab Journal

**Researcher:** Rishabh Kumar

**Project:** Quantum Bio Recovery Engine

**Focus:** Hybrid biological–probabilistic–combinatorial–quantum optimization for therapeutic combination discovery

**Start Date:** Day 1 (Foundation Phase)

---

## Project Vision

To design a reproducible, extensible research platform that models disease biology as a networked system, simulates pharmacological perturbations, formulates therapeutic combination discovery as a Hamiltonian (QUBO) optimization problem, and benchmarks exact, heuristic, and quantum-ready solvers across combinatorial scaling regimes.

Long-term goal: enable hybrid quantum–classical approaches for exploring high-order therapeutic combination spaces where classical exact solvers become computationally impractical.

---

## Day 1 — Foundation & Architecture

### Objectives

* Define a full-stack conceptual pipeline for quantum-assisted drug discovery
* Establish research framing and reproducibility mindset
* Create a lab-style workflow and logging structure

### Conceptual Pipeline

```
Disease / Protein Set
        ↓
Protein Interaction Network (Healthy vs Diseased)
        ↓
Drug Input (SMILES / Known Compounds)
        ↓
Classical Docking & Pre-Filtering
        ↓
Quantum Optimization Layer
        ↓
Systems-Level Network Simulation
        ↓
Bayesian Probability Engine
        ↓
Therapeutic Success & Risk Scores
```

### Notes

* The system is designed to treat biological recovery as a **network perturbation problem** rather than a single-target optimization.
* Optimization layer framed as a **Hamiltonian minimization / QUBO maximization** task, allowing future deployment on quantum hardware.

### Reflection

> Established a hybrid architecture integrating biological modeling, probabilistic inference, and Hamiltonian-based optimization. The system is framed as a reproducible research platform rather than a black-box predictor, enabling benchmarking across classical, heuristic, and quantum solvers.

---

## Day 2 — Disease Network Construction

### Objectives

* Build a protein–protein interaction (PPI) network for a reference disease system (Multiple Sclerosis)
* Validate biological plausibility and pipeline integrity

### Implementation

* Used curated protein set related to immune signaling and myelin biology
* Queried interaction confidence scores from external biological knowledge base (STRING-style model)
* Constructed a weighted graph representation

### Results

**Network Summary:**

* Nodes: 10
* Edges: 35

**Sample Interactions:**

```
IFNG ↔ MBP | confidence=0.667
IFNG ↔ VCAM1 | confidence=0.748
IFNG ↔ MOG | confidence=0.823
IFNG ↔ HLA-DRB1 | confidence=0.830
IFNG ↔ STAT3 | confidence=0.907
IFNG ↔ CD40 | confidence=0.927
IFNG ↔ CXCL10 | confidence=0.959
IFNG ↔ IL2RA | confidence=0.967
IFNG ↔ TNF | confidence=0.991
MBP ↔ HLA-DRB1 | confidence=0.851
```

### Observations

* IFNG emerges as a dominant hub, consistent with immune-centric MS pathology
* Network density validates system coherence and biological relevance

### Reflection

> Successfully constructed a high-confidence MS PPI network and validated hub dominance of IFNG, aligning with known immune-mediated disease mechanisms. This reference network serves as the baseline system state for downstream perturbation and optimization experiments.

---

## Day 3 — Disease Distance Metric

### Objectives

* Define a quantitative measure of system deviation between healthy and perturbed network states

### Metric

**System Disease Distance Score**

* Measures aggregate edge-weight deviation under simulated perturbations
* Interpreted as network-level biological stress

### Sample Outputs

```
System Disease Distance Score: 0.1221
System Disease Distance Score: 1.2708
```

### Interpretation

* Low score → near-baseline state
* High score → strongly perturbed / diseased system

### Reflection

> Introduced a network-level scalar metric capturing global biological deviation, enabling consistent downstream mapping between drug perturbations and system recovery potential.

---

## Day 4 — Drug Recovery Scoring

### Objectives

* Simulate pharmacological perturbations
* Map drug effects onto network recovery space

### Example

**Drug:** Fingolimod
**Recovery Score:** 0.4451

### Interpretation

* Recovery score represents estimated normalization of network topology relative to disease state

### Reflection

> Established a functional mapping from drug perturbations to network recovery metrics, enabling formal comparison between pharmacological candidates.

---

## Day 5 — Probabilistic Modeling

### Objectives

* Convert recovery scores into interpretable success probabilities

### Bayesian Output

```
Probability of Therapeutic Success:
Mean: 0.412
95% CI: (0.255, 0.579)
```

### Notes

* Enables uncertainty-aware ranking of drugs
* Provides statistical framing rather than deterministic scoring

### Reflection

> Added probabilistic interpretation layer, enabling uncertainty quantification and confidence intervals for therapeutic success estimates.

---

## Day 6 — Drug Panel Screening

### Objectives

* Screen multiple drugs under unified probabilistic and recovery framework

### Results

```
=== MS Drug Screening Results ===
1. Fingolimod           | Recovery: 0.629 | P(Success): 0.667 [0.537, 0.785]
2. Dimethyl Fumarate  | Recovery: 0.380 | P(Success): 0.463 [0.333, 0.596]
3. Natalizumab        | Recovery: 0.237 | P(Success): 0.185 [0.094, 0.298]
4. Interferon-beta   | Recovery: 0.166 | P(Success): 0.130 [0.055, 0.230]
```

### Reflection

> Demonstrated rank consistency between network recovery and probabilistic success estimates, validating internal coherence of the modeling stack.

---

## Day 7 — Synergy Discovery

### Objectives

* Identify combinatorial effects between drug pairs

### Results

```
=== MS Combination Synergy Results ===
1. Fingolimod + Dimethyl Fumarate | Recovery: 0.881 | Synergy: 0.252 | P(Success): 0.87
2. Fingolimod + Natalizumab      | Recovery: 0.785 | Synergy: 0.156 | P(Success): 0.704
3. Dimethyl Fumarate + Natalizumab | Recovery: 0.617 | Synergy: 0.237 | P(Success): 0.537
```

### Interpretation

* Synergy metric captures non-linear improvement beyond additive recovery

### Reflection

> Identified dominant therapeutic synergies and established a formal combinatorial scoring framework for drug pair selection.

---

## Day 8 — Hamiltonian Formulation & Optimization

### Objectives

* Encode drug selection as a constrained optimization problem
* Validate Hamiltonian formulation

### Formulation

**Objective:**

Maximize:

```
Σ recovery[i] * x_i + Σ synergy[i][j] * x_i * x_j
```

Subject to:

```
Σ x_i = k
```

### Implementation

* Encoded as QUBO / QuadraticProgram
* Solved using exact minimum eigensolver (NumPy baseline)

### Result

```
Selected drugs:
- Fingolimod
- Dimethyl Fumarate
Objective value: 1.261
```

### Reflection

> Validated Hamiltonian formulation by independently rediscovering the same optimal combination identified by network and synergy layers, confirming cross-layer consistency.

---

## Day 9 — Scaling Benchmarks (k = 3)

### Objectives

* Benchmark optimization hardness
* Compare exact, greedy, and random solvers

### Results

| N  | Exact | Greedy | Random |
| -- | ----- | ------ | ------ |
| 4  | 3.158 | 3.158  | 3.158  |
| 6  | 3.180 | 3.180  | 3.180  |
| 8  | 3.118 | 3.118  | 3.118  |
| 10 | 3.634 | 3.634  | 3.634  |
| 12 | 3.842 | 3.575  | 3.842  |

### Interpretation

* Onset of heuristic failure observed at N ≥ 12
* Greedy solver trapped in local optimum

### Reflection

> Identified transition from polynomially tractable to combinatorially hard regime for k=3 selection, validating need for advanced optimization strategies.

---

## Day 9 — Scaling Benchmarks (k = 4)

### Results

| N  | Exact Time (s) | Exact Value | Greedy Value | Random Value |
| -- | -------------- | ----------- | ------------ | ------------ |
| 8  | 0.0064         | 5.188       | 5.188        | 5.188        |
| 12 | 0.0095         | 5.118       | 5.118        | 4.998        |
| 16 | 0.0260         | 5.065       | 5.065        | 5.034        |
| 20 | 0.1879         | 5.226       | 5.143        | 5.033        |
| 24 | 3.3665         | 5.520       | 5.494        | 5.124        |

### Observations

* Exact solver runtime increased by >500× from N=8 to N=24
* Greedy and random solvers remained constant-time but showed growing optimality gaps

### Reflection

> Demonstrated combinatorial scaling behavior and identified a computational regime where classical exact solvers become impractical and heuristics sacrifice solution quality, motivating hybrid quantum–classical optimization strategies.

---

## Public Release

### Repository

* Name: `quantum-bio-recovery-engine`
* Status: Public

### Research Layer Added

* README.md (scientific front door)
* MIT License
* CITATION.cff
* Curated requirements.txt
* One-command `setup.sh`
* Figures and reproducibility instructions

### Reflection

> Released the full research platform as a public, reproducible repository with experimental logs, figures, and setup automation, establishing academic-grade transparency and collaboration readiness.

---

## Current Status

* Full biological → probabilistic → combinatorial → Hamiltonian → benchmark pipeline operational
* Reproducible environment setup validated
* Scaling curves and figures generated

---

## Next Research Directions

1. Replace exact eigensolver with variational quantum solvers (VQE/QAOA)
2. Deploy on real quantum hardware (IBM Quantum Runtime)
3. Integrate molecular docking (SMILES → binding energy)
4. Extend to multi-disease comparative modeling
5. Publish preprint (arXiv / bioRxiv)

---

## Closing Note

This lab journal documents the full evolution of a hybrid quantum–biological optimization platform from conceptual design through empirical scaling benchmarks and public research release. The system demonstrates a reproducible pathway for exploring combinatorial therapeutic discovery using Hamiltonian-based optimization and quantum-ready computational frameworks.
